SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(DeKosky Steven T.)
 

Search: WFRF:(DeKosky Steven T.) > (2020) > The clinical promis...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

The clinical promise of biomarkers of synapse damage or loss in Alzheimer's disease.

Colom-Cadena, Martí (author)
Spires-Jones, Tara (author)
Zetterberg, Henrik, 1973 (author)
Gothenburg University,Göteborgs universitet,Centrum för åldrande och hälsa (AgeCap),Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi,Centre for Ageing and Health (Agecap),Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry
show more...
Blennow, Kaj, 1958 (author)
Gothenburg University,Göteborgs universitet,Centrum för åldrande och hälsa (AgeCap),Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi,Centre for Ageing and Health (Agecap),Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry
Caggiano, Anthony (author)
DeKosky, Steven T (author)
Fillit, Howard (author)
Harrison, John E (author)
Schneider, Lon S (author)
Scheltens, Phillip (author)
de Haan, Willem (author)
Grundman, Michael (author)
van Dyck, Christopher H (author)
Izzo, Nicholas J (author)
Catalano, Susan M (author)
show less...
 (creator_code:org_t)
2020-03-02
2020
English.
In: Alzheimer's research & therapy. - : Springer Science and Business Media LLC. - 1758-9193. ; 12:1
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • Synapse damage and loss are fundamental to the pathophysiology of Alzheimer's disease (AD) and lead to reduced cognitive function. The goal of this review is to address the challenges of forging new clinical development approaches for AD therapeutics that can demonstrate reduction of synapse damage or loss. The key points of this review include the following: Synapse loss is a downstream effect of amyloidosis, tauopathy, inflammation, and other mechanisms occurring in AD.Synapse loss correlates most strongly with cognitive decline in AD because synaptic function underlies cognitive performance.Compounds that halt or reduce synapse damage or loss have a strong rationale as treatments of AD.Biomarkers that measure synapse degeneration or loss in patients will facilitate clinical development of such drugs.The ability of methods to sensitively measure synapse density in the brain of a living patient through synaptic vesicle glycoprotein 2A (SV2A) positron emission tomography (PET) imaging, concentrations of synaptic proteins (e.g., neurogranin or synaptotagmin) in the cerebrospinal fluid (CSF), or functional imaging techniques such as quantitative electroencephalography (qEEG) provides a compelling case to use these types of measurements as biomarkers that quantify synapse damage or loss in clinical trials in AD.A number of emerging biomarkers are able to measure synapse injury and loss in the brain and may correlate with cognitive function in AD. These biomarkers hold promise both for use in diagnostics and in the measurement of therapeutic successes.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Medicinska och farmaceutiska grundvetenskaper -- Neurovetenskaper (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Basic Medicine -- Neurosciences (hsv//eng)

Publication and Content Type

ref (subject category)
art (subject category)

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view